Back Login to subscribe 🔔 Set Alert

TAK Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

15 min delay

Loading...

Loading...

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

Loading insider data…

Date	Headline	Sentiment
	Jury Hits Takeda With $885 Million Antitrust Verdict	93.53%
	Takeda's Next Wave Of Drugs Has Investors Watching Closely	95.45%
	Earnings Scheduled For May 13, 2026	92.87%
	Takeda Pharmaceutical Co Sees FY2026 GAAP EPS $0.66.	89.87%
	Takeda Pharmaceutical Co Sees FY2026 Adj EPS $3.01; Sees Sales $29.585B	92.84%
	Takeda Pharmaceutical Q4 Adj. EPS $0.28 Beats $0.21 Estimate, Sales $6.978B Miss $7.050B Estimate	80.62%
	BC PharmaCare Reimburses Takeda Canada's REVESTIVE For Eligible Pediatric And Adult Patients	86.2%
	Takeda Announces That The TAK-881-300 Phase 2/3 Clinical Trial In Patients With Primary Immunodeficiency Disease 1 Met Its Primary Endpoint,	79.99%